Document is current
Any future updates will be listed below
-
Authors
Eklöf, Josefin
Alispahic, Imane Achir
Armbruster, Karin
Lapperre, Therese Sophie
Browatzki, Andrea
Overgaard, Rikke Holmen
Harboe, Zitta Barrella
Janner, Julie
Moberg, Mia
Ulrik, Charlotte Suppli
Andreassen, Helle Frost
Weinreich, Ulla Møller
Kjærgaard, Jakob Lyngby
Villadsen, Jenny
Fenlev, Camilla Sund
Jensen, Torben Tranborg
Christensen, Christina Wellendorph
Bangsborg, Jette
Ostergaard, Christian
Ghathian, Khaled Saoud Ali
Jordan, Alexander
Klausen, Tobias Wirenfeldt
Nielsen, Thyge Lynghøj
Wilcke, Torgny
Seersholm, Niels
Sivapalan, Pradeesh
Jensen, Jens-Ulrik Stæhr
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 29 May 2024
First Online: 6 June 2024
Declarations
:
: Written informed consent was obtained from patients before randomisation. The study was approved by the Ethics Committees (H-15010949), the Danish Medicines Agency (EudraCT 2015–003399-58) and the Danish Data Protection Agency (HGH-2017–036, I-Suite nr 05548) and was monitored according to Good Clinical Practice (GCP) by the GCP unit of the Capital Region of Denmark.
: Not relevant.
: The first and last author have no conflicts of interest. CSU reports personal fees from AstraZeneca, GlaxoSmithKline, TEVA, Novartis, Boehringer Ingelheim, TFF Pharmaceuticals, Berlin Chemie, Orion Pharma, Sanofi, Takeda, Pfizer and Chiesi outside of the submitted work. All other authors declare no competing interests.
